News Release
SF State to host Personalized Medicine 3.0 -- Targeting Cancer
Daylong event will highlight advances in biotechnology and applications of personalized medicine
SAN FRANCISCO, May 17, 2010 -- Leaders from Bay Area biotechnology firms will discuss the latest advancements in biotechnology, medicine and cancer treatment at a May 25 personalized medicine conference sponsored by SF State.
"Personalized Medicine 3.0 -- Targeting Cancer" will explore advances in personalized medicine, and how those advances can be used to provide effective and more affordable treatments. Personalized Medicine is the application of genomic data to ensure the delivery of the right treatments and preventive measures to individuals or groups of patients with a similar genetic makeup. Personalized Medicine holds great promise for reducing health care costs and increasing the success of treatments.
The conference will explore what happens when personalized medicine is put into practice, and what that means for caregivers and patients, as well as for the industries that develop products for personalized medicine. This year, the conference concentrates on the role of personalized medicine in optimizing cancer diagnostics and treatment. For more information, visit http://personalizedmedicine.sfsu.edu
Featured speakers and presenters include:
- David Ewing Duncan is an author and National Public Radio correspondent who will discuss his book, "Experimental Man," which follows his experiences being tested for hundreds of chemicals and genes associated with disease and having genetic profiles run of his parents, brother and daughter.
- Napoleone Ferrara, M.D., Genentech fellow, Genentech. Ferrara's studies led to the development of an anti-VEGF antibody, Avastin, which was approved by the FDA in 2004 for the treatment of metastatic colorectal cancer. He was elected to the National Academy of Sciences in 2006.
- Jackie Walling, M.D., Ph.D., vice president, Clinical Development, BioMarin Pharmaceutical, Inc., is a former Medical Director at Tularik where she directed the global clinical development of three anticancer compounds and an antiviral. She is the author or co-author of more than 70 peer-reviewed publications and book chapters.
- J. Martin Tenenbaum, Ph.D., chairman, chief executive officer, chief scientific officer and founder, CollabRx. Tenenbaum will discuss his personal experiences battling cancer and the use of personalized medicine in his treatment.
What: Personalized Medicine 3.0 -- Targeting Cancer
When: May 25 at 9 a.m.
Who: Industry leaders from Bay Area biotechnology firms
Where: Seven Hills Conference Center, San Francisco State University, 1600 Holloway Avenue
- ### -
Share this story:
